^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MYC-BCL2 fusion

    i
    Other names: BCL2, Bcl-2, PPP1R50, B-cell CLL/lymphoma 2, MYC, bHLHe39, c-Myc, MYCC, V-myc avian myelocytomatosis viral oncogene homolog
    Entrez ID:
    4609; 596
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Associations

    News

    Trials
    2years
    Knockout of HMGA1 Promotes ATRA-Induced Differentiation in MLL-Rearranged Leukemia (ASH 2022)
    Although HMGA1 might have little effect on normal hematogenesis, it seemed that HMGA1 had inhibitory effect on ATRA-induced differentiation process of MLL-ENL leukemic cells. Though more conditions including AML types and differentiation methods should be tested and the molecular mechanisms should be scrutinized, there is a possibility that inhibition of HMGA1 is effective in combination with differentiation treatments.
    IO biomarker
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • BCL2 (B-cell CLL/lymphoma 2) • ITGAM (Integrin, alpha M) • HMGA1 (High Mobility Group AT-Hook 1) • MLLT1 (MLLT1 Super Elongation Complex Subunit)
    |
    MLL rearrangement • KIT positive • JAK2 V617F • MYC-BCL2 fusion